Rybakowska, P.van Gassen, S.Perez-Sanchez, C.Ibanez-Costa, A.Varela, N.Castro, R. OrtegaFernandez-Roldan, C.Jimenez-Moleon, I.Ortego, N.Raya, E.Quesada, R. AguilarLopez-Pedrera, C.Estevez, E. CollantesSaeys, Y.Alarcon-Riquelme, M.Maranon, C.2023-05-032023-05-032022-06-010003-4967http://hdl.handle.net/10668/20061Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSC), Sjögren’s syndrome (SJS), mixed connective tissue disease (MCTD), primary antiphospholipid syndrome (PAPS) and undifferentiated connective tissue disease (UCTD) are classified as systemic autoimmune diseases (SADs). They are diagnosed based on different clinical and laboratory criteria. Due to their high internal heterogeneity and overlapping symptoms, SADs are difficult to diagnose. Therefore, molecular and cellular-based studies need to be undertaken to precisely classify the patients. Mass cytometry is a single-cell proteomics technology that measures approximately 50 markers per cell, thus it is a suitable tool to perform deep-phenotyping studies in SADs.enAntiphospholipid syndromeMixed connective tissue diseaseUndifferentiated connective tissue diseasesProteomicsLupus erythematosus, systemicArthritis, rheumatoidScleroderma, systemicHumansconference outputopen accessArtritis reumatoideEsclerodermia sistémicaHumanosLupus eritematoso sistémico10.1136/annrheumdis-2022-eular.11231468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/152.1.full.pdf850279000232